INTERPATH-001
Start here
At ESMO 2026, the intismeran INTerpath-001 results showed a 42% reduction in melanoma recurrence risk and a 38% reduction in the risk related to distant metastasis-free survival. In the same session, in DeLLphi-305, 563 patients with extensive-stage small cell lung cancer received Imdelltra plus Imfinzi, with a 58% reduction in the risk of death; median overall survival was slightly above 21 months versus under 13 months with Imfinzi alone. Nearly half experienced cytokine release syndrome, mostly mild to moderate.
Excerpted from statnews.com
Coverage timeline
Follow the coverage to see the different angles.
- statnews.comPickSTAT+: The ESMO presentation everyone’s been waiting for
At ESMO 2026, the intismeran INTerpath-001 results showed a 42% reduction in melanoma recurrence risk and a 38% reduction in the risk related to distant metastasis-free survival. In the same session, in DeLLphi-305, 563 patients with extensive-stage small cell lung cancer received Imdelltra plus Imfinzi, with a 58% reduction in the risk of death; median overall survival was slightly above 21 months versus under 13 months with Imfinzi alone. Nearly half experienced cytokine release syndrome, mostly mild to moderate.
- x.com#ESMO26
- mp.weixin.qq.comINTerpath-001 Phase 3 Positive While BNT113 Plus Pembrolizumab Misses on PFS, Splitting mRNA Cancer Vaccine Results
Clinical results for mRNA cancer vaccines are diverging. The Phase 3 INTerpath-001 trial read out positive, while BNT113 combined with pembrolizumab failed to significantly improve PFS in first-line treatment.
- biospace.comESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
Phase 3 INTerpath-001 melanoma data leaked unexpectedly ahead of ESMO 2026. Intismeran autogene combined with Keytruda met the primary endpoint, with an RFS hazard ratio of 0.58, corresponding to a 42% reduction in the risk of recurrence or death.
- mp.weixin.qq.comPickINTerpath-001 Data Reportedly Leaked Ahead of ESMO 2026, Moderna Shares Plunge
Detailed INTerpath-001 data appear to have leaked ahead of ESMO 2026, raising efficacy questions and sending Moderna shares sharply lower. According to the original report, after a median follow-up of 24.6 months, adding intismeran to pembrolizumab reduced the risk of recurrence or death, HR = 0.58. At 2 years, 82.2% of patients on the combination were alive and recurrence-free versus 70.0% on pembrolizumab alone.
Heat trend for this story
Heat now 306·Peak in the comparable set 376 (Oct 25 03:00)·Change over 24h in the comparable set +302%·Participants now 53
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.